Veklury
Veklury Appears to Reduce Risk for Long COVID
Remdesivir appears to reduce the risk for certain long COVID-19 symptoms in people who were hospitalized for ...
MARCH 7, 2024
Veklury Reduces Mortality in Immunocompromised People With COVID-19
Veklury can have significant benefits for immunocompromised people with COVID-19, reducing mortality by 30%.
FEBRUARY 15, 2024
FDA Grants New Indication for Veklury to Treat COVID-19 in People With Hepatic Impairment
The FDA granted a supplemental new drug application for the use of remdesivir with no dose adjustments to treat ...
AUGUST 25, 2023
FDA Expands Indication for Veklury to Treat COVID-19 Patients With Renal Impairment
With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across ...
JULY 28, 2023
Remdesivir-Resistant Version of COVID-19 Detected in Organ Transplant Recipients
Two kidney transplant patients treated with immunosuppressive drugs, and who later had a lengthy COVID-19 ...
NOVEMBER 8, 2022
FDA Approves Veklury, First COVID-19 Treatment for Young Children
The FDA expanded the approval of the COVID-19 drug remdesivir (Veklury, Gilead) to include pediatric patients 28 ...
APRIL 27, 2022
Remdesivir Resistance Found in Immunocompromised Patient
Yale researchers said the discovery raised concerns about the emergence of drug resistance in COVID-19 patients, ...
MARCH 24, 2022
Addition of IVIG Does Not Improve COVID-19 Outcomes
Outcomes for patients hospitalized for COVID-19 who received remdesiver plus IVIG were not better than remdesivir ...
JANUARY 28, 2022
FDA Expands Use of Veklury for Mild to Moderate COVID-19
Previously limited to hospitalized patients, The FDA expands use of remdesivir to the outpatient setting.
JANUARY 24, 2022